Pathophysiology of myocardial infarction. Protection by ischemic pre- and postconditioning

Herz

Volumn 33, Issue 2, 2008, Pages 88-100

  Skyschally, Andreas ^b   Schulz, Rainer ^b   Heusch, Gerd ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Universitätsklinikum Essen ^*

Author keywords

Ischemic postconditioning; Ischemic preconditioning; Myocardial infarction; Reperfusion injury

Indexed keywords

CONNEXIN 43; PROTEIN KINASE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

DISEASE MODEL; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; MITOCHONDRION; NONHUMAN; PATHOPHYSIOLOGY; REPERFUSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; SIGNAL TRANSDUCTION;

EID: 41149145607     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-008-3101-9     Document Type: Review

References (184)

1. Abdallah Y, Gkatzoflia A, Pieper H, et al. Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury. Cardiovasc Res 2005;66:123-31.
2. Andreka G, Vertesaljai M, Szantho G, et al. Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigs. Heart 2007;93:749-52.
3. Azzam EI, de Toledo SM, Little JB. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha-particle irradiated to nonirradiated cells. Proc Natl Acad Sci U S A 2001;98:473-8.
4. Baines CP, Wang L, Cohen MV, et al. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J Mol Cell Cardiol 1998;30:383-92.
5. Bao X, Reuss L, Altenberg GA. Regulation of purified and reconstituted connexin 43 hemichannels by protein kinase C-mediated phosphorylation of serine 368. J Biol Chem 2004;279:20058-66.
6. Barrabés JA, Garcia-Dorado D, Ruiz-Meana M, et al. Myocardial segment shrinkage during coronary reperfusion in situ. Relation to hypercontracture and myocardial necrosis. Pflügers Arch 1996;431:519-26.
7. Behrends M, Schulz R, Post H, et al. Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs. Am J Physiol Heart Circ Physiol 2000;279:H1111-9.
8. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41:508-15.
9. Billinger M, Fleisch M, Eberli FR, et al. Is the development of myocardial tolerance to repeated ischemia in humans due to preconditioning or to collateral recruitment? J Am Coll Cardiol 1999;33:1027-35.
10. Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. Physiol Rev 1999;79:763-854.
11. Boengler K, Buechert A, Heinen Y, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008;102:131-5.
12. Boengler K, Dodoni G, Ruiz-Meana M, et al. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 2005;67:234-44.
13. Boengler K, Konietzka I, Buechert A, et al. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 2007;292:H1764-9.
14. Bolli R. The late phase of preconditioning. Circ Res 2000;87:972-83.
15. Bolli R, Dawn B, Tang X-L, et al. The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol 1998;93:325-38.
16. Bolli R, Dawn B, Yuan Y-T. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 2003;13:72-9.
17. Cohen MV, Philipp S, Krieg T, et al. Preconditioning-mimetics bradykinin and DADLE activate PI3-kinase through divergent pathways. J Mol Cell Cardiol 2007;42:842-51.
18. Cohen MV, Yang X-M, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 2007;115:1895-903.
19. Cohen MV, Yang X-M, Liu GS, et al. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial KATP channels. Circ Res 2001;89:273-8.
20. Darling CE, Solari PB, Smith CS, et al. "Postconditioning" the human heart: Multiple balloon inflations during primary angioplasty may confer cardioprotection. Basic Res Cardiol 2007;102:274-8.
21. Dawn B, Guo Y, Rezazadeh A, et al. Tumor necrosis factor-α does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 2004;37:51-61.
22. De Maio A, Vega VL, Contreras JE. Gap junctions, homeostasis, and injury. J Cell Physiol 2002;191:269-82.
23. Deutsch E, Berger M, Kussmaul WG, et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation 1990;82:2044-51.
24. Diaz RJ, Armstrong SC, Batthish M, et al. Enhanced cell volume regulation: a key protective mechanism of ischemic preconditioning in rabbit ventricular myocytes. J Mol Cell Cardiol 2003;35:45-58.
25. Di Lisa F, Canton M, Menabó R, et al. Mitochondria and reperfusion injury. The role of permeability transition. Basic Res Cardiol 2003;98:235-41.
26. Di Napoli P, Taccardi AA, Grilli A, et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005;66:462-71.
27. Dörge H, Neumann T, Behrends M, et al. Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am J Physiol Heart Circ Physiol 2000;279:H2587-92.
28. Dörge H, Schulz R, Belosjorow S, et al. Coronary microembolization: the role of TNFα in contractile dysfunction. J Mol Cell Cardiol 2002;34:51-62.
29. Downey JM, Cohen MV. We think we see a pattern emerging here. Circulation 2005;111:120-1.
30. Ebel D, Müllenheim J, Fräßdorf J, et al. Effect of acute hyperglycaemia and diabetes mellitus with and without short-term insulin treatment on myocardial ischaemic late preconditioning in the rabbit heart in vivo. Pflügers Arch 2003;446:175-82.
31. Ek-Vitorin JF, King TJ, Heyman NS, et al. Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circ Res 2006;98:1498-505.
32. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007;59:418-58.
33. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 2007;102:279-97.
34. Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 2001;88:802-9.
35. Förster K, Paul I, Solenkova N, et al. NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res Cardiol 2006;101:319-26.
36. Fujita M, Asanuma H, Hirata A, et al. Prolonged transient acidosis during early reperfusion contributes to the cardioprotective effects of postconditioning. Am J Physiol Heart Circ Physiol 2007;292:H2004-8.
37. Garcia-Dorado D, Oliveras J. Myocardial edema: a preventable cause of reperfusion injury. Cardiovasc Res 1993;27:1555-63.
38. Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M. Gap junction-mediated spread of cell injury and death during myocardial ischemia-reperfusion. Cardiovasc Res 2004;61:386-401.
39. Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, et al. The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion. Cardiovasc Res 2006;70:274-85.
40. Garcia-Dorado D, Theroux P, Desco M, et al. Cell-to-cell interaction: a mechanism to explain wave-front progression of myocardial necrosis. Am J Physiol 1989;256:H1266-73.
41. Garcia-Dorado D, Théroux P, Duran JM, et al. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation 1992;85:1160-74.
42. Gres P, Schulz R, Jansen J, et al. Involvement of endogenous prostaglandins in ischemic preconditioning in pigs. Cardiovasc Res 2002;55:626-32.
43. Gross ER, Hsu AK, Gross GJ. GSK3beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res Cardiol 2007;102:341-9.
44. Guo Y, Jones WK, Xuan YT, et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 1999;96:11507-12.
45. Guo Y, Li Q, Wu W-J, et al. Endothelial nitric oxide synthase is not necessary for the early phase of ischemic preconditioning in the mouse. J Mol Cell Cardiol 2008:in press.
46. Hartman JC, Wall TM, Hullinger TG, et al. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.
47. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 2004;63:305-12.
48. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. Lancet 2007;370:575-9.
49. Hausenloy DJ, Tsang A, Mocanu MM, et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005;288:H971-6.
50. Hausenloy DJ, Wynne AM, Yellon DM. Ischemic preconditioning targets the reperfusion phase. Basic Res Cardiol 2007;102:445-52.
51. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-60.
52. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006;70:240-53.
53. Hausenloy DJ, Yellon DM. The evolving story of "conditioning" to protect against acute myocardial ischaemia-reperfusion injury. Heart 2007;93:649-51.
54. Heidland UE, Heintzen MP, Michel CJ, et al. Effect of adjunctive intracoronary adenosine on myocardial ischemia, hemodynamic function and left ventricular performance during percutaneous transluminal coronary angioplasty: clinical access to ischemic preconditioning? Coron Artery Dis 2000;11:421-8.
55. Heinzel FR, Luo Y, Li X, et al. Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. Circ Res 2005;97:583-6.
56. Heusch G. Nitroglycerin and delayed preconditioning in humans. Yet another new mechanism for an old drug? Circulation 2001;103:2876-8.
57. Heusch G. Postconditioning. Old wine in a new bottle? J Am Coll Cardiol 2004;44:1111-2.
58. Heusch G. Obesity - a risk factor or a RISK factor for myocardial infarction? Br J Pharmacol 2006;149:1-3.
59. Heusch G, Büchert A, Feldhaus S, et al. No loss of cardioprotection by postconditioning in connexin 43-deficient mice. Basic Res Cardiol 2006;101:354-6.
60. Heusch G, Cohen MV, Downey JM. Ischemic preconditioning through opening of swelling-activated chloride channels ? Circ Res 2001;89:e48.
61. Heusch G, Schulz R. Little evidence for lethal reperfusion injury to cardiomyocytes. J Thromb Thrombolysis 1997;4:111-2.
62. Heusch G, Schulz R. Remote preconditioning. J Mol Cell Cardiol 2002;34:1279-81.
63. Heusch G, Schulz R. The role of heart rate and the benefits of heart rate reduction in acute myocardial ischaemia. Eur Heart J 2007;9:Suppl F:F8-14.
64. Heusch P, Skyschally A, Leineweber K, et al. The interaction of coronary microembolization and ischemic preconditioning: a third window of cardioprotection through TNF-alpha. Arch Med Sci 2007;2:83-92.
65. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589-600.
66. Hoshida S, Yamashita N, Otsu K, et al. The importance of manganese superoxide dismutase in delayed preconditioning: involvement of reactive oxygen species and cytokines. Cardiovasc Res 2002;55:495-505.
67. Ichikawa Y, Miura T, Nakano A, et al. The role of ADAM protease in the tyrosine kinase-mediated trigger mechanism of ischemic preconditioning. Cardiovasc Res 2004;62:167-75.
68. Iliodromitis EK, Gaitanaki C, Lazou A, et al. Differential activation of mitogen-activated protein kinases in ischemic and nitroglycerin-induced preconditioning. Basic Res Cardiol 2006;101:327-35.
69. Iliodromitis EK, Georgiadis M, Cohen MV, et al. Protection from postconditioning depends on the number of short ischemic insults in anesthetized pigs. Basic Res Cardiol 2006;101:502-7.
70. Iliodromitis EK, Zoga A, Vrettou A, et al. The effectiveness of postconditioning and preconditioning on infarct size in hypercholesterolemic and normal anesthetized rabbits. Atherosclerosis 2006;188:356-62.
71. Inserte J, Garcia-Dorado D, Hernando V, et al. Calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia. Circ Res 2005;97:465-73.
72. Inserte J, Garcia-Dorado D, Ruiz-Meana M, et al. Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism. Cardiovasc Res 2004;64:105-14.
73. Ishihara M, Sato H, Tateishi H, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol 1997;30:970-5.
74. Jain SK, Schuessler RB, Saffitz JE. Mechanisms of delayed electrical uncoupling induced by ischemic preconditioning. Circ Res 2003;92:1138-44.
75. Jalowy A, Schulz R, Dörge H, et al. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998;32:1787-96.
76. Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol 1998;93:Suppl 2:85-91.
77. Jenkins DP, Pugsley WB, Alkhulaifi AM, et al. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 1997;77:314-8.
78. Jugdutt BI, Xu Y, Balghith M, et al. Cardioprotective effects of angiotensin II type 1 receptor blockade with candesartan after reperfused myocardial infarction: role of angiotensin II type 2. JRAAS 2001;2: Suppl 1:S162-6.
79. Juhaszova M, Zorov DB, Kim S-H, et al. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004;113:1535-49.
80. Kerendi F, Kin H, Halkos ME, et al. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005;100:404-12.
81. Kersten JR, Toller WG, Gross ER, et al. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000;278:H1218-24.
82. Kin H, Zhao Z-Q, Sun H-Y, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004;62:74-85.
83. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995;91:37-47.
84. Ladilov YV, Siegmund B, Piper HM. Protection of reoxygenated cardiomyocytes against hypercontracture by inhibition of Na+/H+ exchange. Am J Physiol 1995;268:H1531-9.
85. Landmark K, Abdelnoor M, Kilhovd B, et al. Infarct size as estimated from peak creatine kinase and lactate dehydrogenase is probably reduced in patients using calcium antagonists at the onset of symptoms. Cardiovasc Drugs Ther 1997;11:557-65.
86. Lang SC, Elsässer A, Scheler C, et al. Myocardial preconditioning and remote renal preconditioning. Identifying a protective factor using proteomic methods? Basic Res Cardiol 2006;101:149-58.
87. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1999;99:2085-9.
88. Lecour S, Rochette L, Opie L. Free radicals trigger TNFα-induced cardioprotection. Cardiovasc Res 2005;65:239-43.
89. Lecour S, Smith RM, Woodward B, et al. Identification of a novel role for sphingolipid signaling in TNFα and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002;34:509-18.
90. Lecour S, Suleman N, Deuchar GA, et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005;112:3911-8.
91. Lee T-M, Su S-F, Chou T-T, et al. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 2002;105:334-40.
92. Leesar MA, Stoddard M, Ahmed M, et al. Preconditioning in human myocardium with adenosine during coronary angioplasty. Circulation 1997;95:2500-7.
93. Leesar MA, Stoddard MF, Dawn B, et al. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001;103:2935-41.
94. Leesar MA, Stoddard MF, Manchikalapudi S, et al. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 1999;34:639-50.
95. Li X, Heinzel FR, Boengler K, et al. Role of connexin 43 in ischemic preconditioning does not involve intercellular communications through gap junctions. J Mol Cell Cardiol 2004;36:161-3.
96. Maeng M, Mortensen UM, Kristensen J, et al. Hypothermia during reperfusion does not reduce myocardial infarct size in pigs. Basic Res Cardiol 2006;101:61-8.
97. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.
98. Manintveld OC, Te Lintel HM, van den Bos EJ, et al. Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol 2007;292:H1551-60.
99. Marber MS, Latchman DS, Walker JM, et al. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993;88:1264-72.
100. Martin C, Schulz R, Post H, et al. Microdialysis-based analysis of interstitial NO in situ: NO synthase-independent NO formation during myocardial ischemia. Cardiovasc Res 2007;74:46-55.
101. Matsumura K, Jeremy RW, Schaper J, et al. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998;97:795-804.
102. Maulik N, Yoshida T, Zu Y-L, et al. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol 1998;275:H1857-64.
103. Michel MC, Li Y, Heusch G. Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol 2001;363:245-66.
104. Miki T, Miura T, Tanno M, et al. Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts. Mol Cell Biochem 2003;247:185-93.
105. Miki T, Miura T, Tsuchida A, et al. Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation. Circulation 2000;102:458-63.
106. Miura T, Ohnuma Y, Kuno A, et al. Protective role of gap junctions in preconditioning against myocardial infarction. Am J Physiol Heart Circ Physiol 2004;286:H214-21.
107. Moolman JA, Genade S, Tromp E, et al. Ischaemic preconditioning does not protect hypertrophied myocardium against ischaemia. S Afr Med J 1997;87:Suppl 3:C151-6.
108. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
109. Mykytenko J, Kerendi F, Reeves JG, et al. Long-term inhibition of myocardial infarction by postconditioning during reperfusion. Basic Res Cardiol 2007;102:90-100.
110. Nakagawa Y, Ito H, Kitakaze M, et al. Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of "preconditioning". J Am Coll Cardiol 1995;25:1076-83.
111. Nakano A, Liu GS, Heusch G, et al. Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J Mol Cell Cardiol 2000;32:1159-67.
112. Okamoto F, Allen BS, Buckberg GD, et al. Studies of controlled reperfusion after ischemia. XIV. Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg 1986;92:613-20.
113. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size. A role for ischemic preconditioning. Circulation 1995;91:291-7.
114. ATP channels triggers the preconditioned state by generating free radicals. Circ Res 2000;87:460-6.
115. Penna C, Mancardi D, Tullio F, et al. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 2008:in press.
116. Penna C, Rastaldo R, Mancardi D, et al. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol 2006;101:180-9.
117. Piper HM, Abdallah Y, Schäfer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 2004;61:365-71.
118. Plotkin LI, Manolagas SC, Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 2002;277:8648-57.
119. Post H, Schulz R, Behrends M, et al. No involvement of endogenous nitric oxide in classical ischemic preconditioning in swine. J Mol Cell Cardiol 2000;32:725-33.
120. Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-9.
121. Przyklenk K, Darling CE, Dickson EW, et al. Cardioprotection "outside the box". The evolving paradigm of remote preconditioning. Basic Res Cardiol 2003;98:149-57.
122. ATP-dependent mechanism. Am J Physiol Heart Circ Physiol 2004;287:H712-8.
123. Quist AP, Rhee SK, Lin H, et al. Physiological role of gap-junctional hemichannels. Extracellular calcium-dependent isoosmotic volume regulation. J Cell Biol 2000;148:1063-74.
124. Raggi P, Dickson NR, Boyne M, et al. Influence of prior ACE inhibitor therapy on morbidity and mortality following acute myocardial infarction. Ann Pharmacother 1998;32:1141-6.
125. Reimer KA, Jennings RB, Cobb FR, et al. Animal models for protecting ischemic myocardium: results of the NHLBI cooperative study. Comparison of unconscious and conscious dog models. Circ Res 1985;56:651-65.
126. Rodriguez-Sinovas A, Garcia-Dorado D, Ruiz-Meana M, et al. Protective effect of gap junction uncouplers given during hypoxia against reoxygenation injury in isolated rat hearts. Am J Physiol Heart Circ Physiol 2006;290:H648-56.
127. Ruiz-Meana M, Abellan A, Miro-Casas E, et al. Opening of mitochondrial permeability transition pore induces hypercontracture in Ca2+ overloaded cardiac myocytes. Basic Res Cardiol 2007;102:542-52.
128. Ruiz-Meana M, Rodriguez-Sinovas A, Cabestrero A, et al. Mitochondrial connexin43 as a new player in the pathophysiology of myocardial ischaemia reperfusion injury. Cardiovasc Res 2008;77:325-33.
129. Rutherford JD, Pfeffer MA, Mojé LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. Circulation 1994;90:1731-8.
130. Ruusalepp A, Czibik G, Flatebo T, et al. Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases. Basic Res Cardiol 2007;102:318-26.
131. Sanada S, Kitakaze M, Papst PJ, et al. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circ Res 2001;88:175-80.
132. Sato H, Bolli R, Rokosh GD, et al. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. Am J Physiol Heart Circ Physiol 2007;293:H2557-64.
133. 2+ exchanger in reoxygenation-induced cardiomyocyte injury. Cardiovasc Res 2001;51:241-50.
134. Schaper W, Görge G, Winkler B, et al. The collateral circulation of the heart. Prog Cardiovasc Dis 1988;31:57-77.
135. Schaper W, Schaper J. Reperfusion injury: an opinionated view. J Thromb Thrombolysis 1997;4:113-6.
136. Schlüter KD, Jakob G, Ruiz-Meana GJM, et al. Protection of reoxygenated cardiomyocytes against osmotic fragility by nitric oxide donors. Am J Physiol 1996;271:H428-34.
137. Schulz R, Belosjorow S, Gres P, et al. p38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovasc Res 2002;55:690-700.
138. Schulz R, Boengler K, Totzeck A, et al. Connexin 43 in ischemic pre- and postconditioning. Heart Fail Rev 2007;12:261-6.
139. Schulz R, Cohen MV, Behrends M, et al. Signal transduction of ischemic preconditioning. Cardiovasc Res 2001;52:181-98.
140. Schulz R, Gres P, Heusch G. Role of endogenous opioids in ischemic preconditioning but not in short-term hibernation in pigs. Am J Physiol Heart Circ Physiol 2001;280:H2175-81.
141. Schulz R, Gres P, Konietzka I, et al. Regional differences of myocardial infarct development and ischemic preconditioning. Basic Res Cardiol 2005;100:48-56.
142. Schulz R, Gres P, Skyschally A, et al. Ischemic preconditioning preserves connexin 43 phosphorylation during sustained ischemia in pig hearts in vivo. FASEB J 2003;17:1355-7.
143. 1-receptor blockade in experimental myocardial ischaemia/reperfusion. JRAAS 2001;2:Suppl 1:S136-40.
144. Schulz R, Heusch G. AT1-receptor blockade in experimental myocardial ischemia/reperfusion. Clin Nephrol 2003;60:Suppl 1:S67-74.
145. Schulz R, Post H, Jalowy A, et al. Unique cardioprotective action of the new calcium antagonist mibefradil. Circulation 1999;99:305-11.
146. Schulz R, Post H, Vahlhaus C, et al. Ischemic preconditioning in pigs: a graded phenomenon. Its relation to adenosine and bradykinin. Circulation 1998;98:1022-9.
147. Schulz R, Rose J, Post H, et al. Involvement of endogenous adenosine in ischaemic preconditioning in swine. Pflügers Arch 1995;430:273-82.
148. Schulz R, Rose J, Skyschally A, et al. Bradycardic agent UL-FS 49 attenuates ischemic regional dysfunction and reduces infarct size in swine: comparison with the β-blocker atenolol. J Cardiovasc Pharmacol 1995;25:216-28.
149. Schwanke U, Konietzka I, Duschin A, et al. No ischemic preconditioning in heterozygous connexin43-deficient mice. Am J Physiol Heart Circ Physiol 2002;283:H1740-2.
150. Schwanke U, Li X, Schulz R, et al. No ischemic preconditioning in heterozygous connexin 43-deficient mice: a further in vivo study. Basic Res Cardiol 2003;98:181-2.
151. Schwartz LM, Lagranha CJ. Ischemic postconditioning during reperfusion activates Akt and ERK without protecting against lethal myocardial ischemia-reperfusion injury in pigs. Am J Physiol Heart Circ Physiol 2006;290:H1011-8.
152. Shinmura K, Bolli R, Liu S-Q, et al. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res 2002;91:240-6.
153. Skyschally A, Gres P, Hoffmann S, et al. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 2007;100:140-6.
154. Skyschally A, Leineweber K, Gres P, et al. Coronary microembolization. Basic Res Cardiol 2006;101:373-82.
155. Skyschally A, Schulz R, Gres P, et al. Attenuation of ischemic preconditioning in pigs by scavenging of free oxyradicals with ascorbic acid. Am J Physiol Heart Circ Physiol 2003;284:H698-703.
156. Skyschally A, Schulz R, Gres P, et al. Coronary microembolization does not induce acute preconditioning against infarction in pigs - the role of adenosine. Cardiovasc Res 2004;63:313-22.
157. Smith RM, Suleman N, Lacerda L, et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004;63:611-6.
158. Smith RM, Suleman N, McCarthy J, et al. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFα gene. Cardiovasc Res 2002;55:553-60.
159. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005;112:2143-8.
160. Szilvassy Z, Ferdinandy P, Szilvassy J, et al. The loss of pacing-induced preconditioning in atherosclerotic rabbits: role of hypercholesterolaemia. J Mol Cell Cardiol 1995;27:2559-69.
161. 2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Circ Res 1989;65:1045-56.
162. Thibault H, Piot C, Staat P, et al. Long term benefit of postconditioning. Circulation 2008:in press.
163. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994;90:700-5.
164. Tomai F, Crea F, Gaspardone A, et al. Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 1999;33:1863-9.
165. Turcato S, Turnbull L, Wang G-Y, et al. Ischemic preconditioning depends on age and gender. Basic Res Cardiol 2006;101:235-43.
166. Vahlhaus C, Schulz R, Post H, et al. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res 1996;79:407-14.
167. Vahlhaus C, Schulz R, Post H, et al. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol 1998;30:197-209.
168. Valen G, Hinokiyama K, Vedin J, et al. Preoperative unstable angina causes venous adaptation to surgical graft injury. Basic Res Cardiol 2007;102:265-73.
169. Valen G, Vaage J. Pre- and postconditioning during cardiac surgery. Basic Res Cardiol 2005;100:179-86.
170. Vinten-Johansen J, Yellon DM, Opie LH. Postconditioning. A simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation 2005;112:2085-8.
171. Vinten-Johansen J, Zhao Z-Q, Zatta AJ, et al. Postconditioning. A new link in nature's armor against myocardial ischemia-reperfusion injury. Basic Res Cardiol 2005;295:295-310.
172. 1-receptor antagonism. Br J Pharmacol 2000;131:138-44.
173. Xiao RP, Cheng H, Zhou YY, et al. Recent advances in cardiac β2-adrenergic signal transduction. Circ Res 1999;85:1092-100.
174. Xuan Y-T, Guo Y, Han H, et al. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci U S A 2001;98:9050-5.
175. Xuan Y-T, Guo Y, Zhu Y, et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol 2003;35:525-37.
176. Xuan Y-T, Guo Y, Zhu Y, et al. Role of the protein kinase C-e-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation 2005;112:1971-8.
177. Yamashita N, Hoshida S, Otsu K, et al. Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. J Exp Med 1999;189:1699-706.
178. Yang X-M, Philipp S, Downey JM, et al. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005;100:57-63.
179. Yang X-M, Proctor JB, Cui L, et al. Multiple, brief coronary occlusions during early reperfusion protect hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004;44:1103-10.
180. Yang X-M, Sato H, Downey JM, et al. Protection of ischemic preconditioning is dependent upon a critical timing sequence of protein kinase C activation. J Mol Cell Cardiol 1997;29:991-9.
181. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993;342:276-7.
182. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113-51.
183. Zhao Z-Q, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-88.
184. Zmudka K, Dubiel J, Vanhaecke J, et al. Effects of oral pretreatment with metoprolol on left ventricular wall motion, infarct size, hemodynamics, and regional myocardial blood flow in anesthetized dogs during thrombotic coronary artery occlusion and reperfusion. Cardiovasc Drugs Ther 1994;8:479-87.